“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Glyburide (Glyburide)

Trade Name : Glyburide

Hikma Pharmaceuticals USA Inc.

TABLET

Strength 1.5 mg/1

GLYBURIDE Sulfonylurea [EPC],Sulfonylurea Compounds [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Glyburide (Glyburide) which is also known as Glyburide and Manufactured by Hikma Pharmaceuticals USA Inc.. It is available in strength of 1.5 mg/1 per ml. Read more

Glyburide (Glyburide) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • No data
  • Glyburide Tablets, USP (micronized) contain micronized (smaller particle size) glyburide, which is an oral blood-glucose-lowering drug of the sulfonylurea class. Glyburide is a white, crystalline compound, formulated as Glyburide Tablets, USP (micronized) tablets of 1.5 mg, 3 mg, and 6 mg strengths for oral administration. Inactive ingredients: colloidal silicon dioxide, pregelatinized maize starch, lactose monohydrate, magnesium stearate. In addition, the strength contains FD&C Blue No. 1 Aluminum Lake, and the tablet contains D&C Yellow No. 10 Aluminum Lake. The chemical name for glyburide is 1-[[p-[2-(5-chloro-o-anisamido) ethyl]phenyl]-sulfonyl]-3-cyclohexylurea and the molecular weight is 493.99. The structural formula is represented below:
  • Glyburide Tablets meet USP Dissolution Test 5.
  • No data
  • Glyburide Tablets, USP (micronized) are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Glyburide tablets (micronized) are contraindicated in patients with:
  • 1. Known hypersensitivity or allergy to the drug.
  • 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
  • 3. Type I diabetes mellitus.
  • 4. Concomitant administration of bosentan.
  • The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (19 (Suppl. 2):747-830, 1970).
  • UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2 1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glyburide tablets (micronized) and of alternative modes of therapy.
  • Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.
  • Macrovascular Outcomes:
  • Bioavailability studies have demonstrated that glyburide tablets (micronized) 3 mg provide serum glyburide concentrations that are not bioequivalent to those from glyburide tablets (nonmicronized) 5 mg. Therefore, patients should be retitrated when transferred from glyburide tablets (nonmicronized) or other oral hypoglycemic agents.
  • Hypoglycemia: n- Arrayn- Array
  • Gastrointestinal Reactions:
  • Liver function abnormalities, including isolated transaminase elevations, have been reported.
  • Gastrointestinal disturbances, , nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced.
  • Dermatologic Reactions: n- eg
  • Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.
  • Hematologic Reactions: n- Array
  • Metabolic Reactions:
  • Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.
  • Other Reactions:
  • In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia and vasculitis have been reported.
  • To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-233-2001, or FDA at 1-800-FDA-1088 or u00a0
  • Overdosage of sulfonylureas, including glyburide, can produce hypoglycemia. Mild hypoglycemic symptoms, without loss of consciousness or neurological findings, should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.
  • Patients should be retitrated when transferred from glyburide tablets (nonmicronized) or other oral hypoglycemic agents.
  • There is no fixed dosage regimen for the management of diabetes mellitus with glyburide tablets (micronized). In addition to the usual monitoring of urinary glucose, the patientu2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, , inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, , loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patientu2019s response to therapy.
  • Short-term administration of glyburide (micronized) may be sufficient during periods of transient loss of control in patients usually controlled well on diet.
  • u00a0
  • u00a0
  • u00a0
  • Glyburide Tablets, USP (micronized) 1.5 mg:
  • Bottles of 100 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9918-01
  • Bottles of 500 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9918-05
  • Glyburide Tablets, USP (micronized) 3 mg:
  • Bottles of 100 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9919-01
  • Bottles of 500 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9919-05
  • Bottles of 1000u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0NDC 0143-9919-10
  • Glyburide Tablets, USP (micronized) 6 mg:
  • Bottles of 100 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9920-01
  • Bottles of 500 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0 u00a0u00a0u00a0u00a0NDC 0143-9920-05
  • Bottles of 1000u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0NDC 0143-9920-10
  • Glyburide Tablets, USP (micronized) can be divided in half for a more flexible dosing regimen. Press gently on the score and the tablet will split in even halves.
  • Rx only
  • Store at 20u00ba to 25u00baC (68u00ba to 77u00baF) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed.
  • Distributed by:
  • West-Ward Pharmaceuticals Corp.
  • Eatontown, NJ 07724
  • Manufactured by:
  • HIKMA Pharmaceuticals
  • P.O. Box 182400
  • Amman 11118 u2013 Jordan
  • Revised September 2017
  • NDC 0143-9918-01GlyBURIDE Tablets, USP(micronized)1.5 mg100 TabletsRx Only
  • NDC 0143-9919-01GlyBURIDE Tablets, USP(micronized)3 mg100u00a0TABLETSRx Only
  • NDC 0143-9920-01GlyBURIDE Tablets, USP(micronized)6 mg100 TabletsRx Only

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.